Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.
- Record quarterly revenue of $3.8 million, up 20% from prior quarter
- FY2026 revenue climbs 44% to $13.2 million
- US Remplir sales and hospital adoption accelerate
- Regulatory approval for UK/EU Remplir expected by end 2026
- Strong cash reserves of $44.1 million underpin expansion
Record Revenue Growth Driven by Remplir and Striate+
Orthocell Limited (ASX:OCC) has delivered a milestone quarter with record revenue of $3.8 million for Q4 FY2026, marking a 20% increase on the previous quarter and a 36% jump from the same period last year. This pushed full-year revenue to a new high of $13.2 million, up 44% year-on-year, fuelled by strong adoption of its regenerative medicine products Remplir™ and Striate+™ across Australia, the US, and emerging international markets.
The company’s quarterly revenue has grown at a compound rate of 10% over the past 10 quarters, reflecting sustained commercial momentum. International sales now account for over 9% of quarterly revenue, with new distributor appointments in Canada and Thailand and plans to launch in the UK and EU in early 2027.
US Commercial Rollout Outpaces Expectations
Orthocell’s US commercialisation of Remplir continues to gather pace, with sales reaching $0.33 million in the quarter, a 10% increase from March. The company has expanded its distributor network to cover approximately half of the US population. Crucially, Value Analysis Committee approvals jumped 38% to 44, opening access to 151 hospitals, while 70 hospitals are now purchasing Remplir, a 27% increase, and surgeon users rose 55% to 76.
Significant progress includes approval for Remplir use across the US Department of Defense and Veterans Affairs healthcare networks, granting access to 221 military and veterans' medical centres. Orthocell’s commercial platform is positioning the company for accelerated revenue growth as hospital adoption deepens and repeat surgeon usage emerges. The company also hosted nine medical education events to promote Remplir’s advanced nerve repair capabilities among surgeons.
Strong Cash Position Supports Global Expansion
Orthocell ended the quarter with $44.1 million in available funds, including $9.4 million in cash and $34.7 million in term deposits. This robust liquidity supports ongoing US commercialisation, regulatory initiatives, manufacturing scale-up, and strategic growth without the need for additional funding. The company maintains disciplined cost management while expanding manufacturing capacity and targeting cash flow breakeven.
Regulatory and Market Developments in UK/EU and Asia
The regulatory submission for Remplir’s commercial approval in the UK and EU remains on track with the British Standards Institution, with approval expected by the end of 2026. Preparations with UK distributor LEDA Orthopaedics include training and launch planning to capitalise on a market estimated at US$750 million.
International expansion also advanced with regulatory approvals for the Striate+ dental product in Colombia and Ecuador, enabling imminent market launches alongside BioHorizons, Orthocell’s global distribution partner. Sales in Brazil, Colombia, and Ecuador are expected to commence in the second half of 2026, supporting manufacturing scale-up efficiencies shared with Remplir.
Clinical and Humanitarian Initiatives Highlight Product Potential
Orthocell is advancing the use of Remplir in nerve-sparing prostate cancer surgery, with over 250 procedures performed by 39 surgeons across Australia. This new indication could expand the US market opportunity from US$1.6 billion to approximately US$2 billion. Clinical outcome data are being compiled, with results expected in the second half of 2026 following academic publication.
On the humanitarian front, Remplir devices continue to be shipped to Ukraine to aid treatment of complex trauma injuries, demonstrating the product’s suitability for battlefield conditions. Further humanitarian programs are planned, with commercial opportunities to follow where NGO support is involved.
Expanding Product Pipeline and Future Catalysts
Orthocell has initiated a US regulatory program for a tendon repair application leveraging its collagen technology platform, broadening its regenerative medicine portfolio. This new indication complements existing products and targets a significant unmet clinical need, with no additional FDA approvals required for the prostate surgery indication.
CEO Paul Anderson highlighted the company’s strong FY2026 performance as evidence of successful global commercialisation execution. He pointed to the upcoming regulatory approval in the UK/EU and continued US market penetration as key near-term catalysts. Orthocell’s focus on manufacturing scale-up, commercial expansion, and clinical research investment aims to sustain its growth trajectory.
Bottom Line?
Orthocell’s record revenue and strong cash reserves position it well for growth, but upcoming clinical data releases and UK/EU regulatory approval will be critical to validate market expansion prospects.
Questions in the middle?
- How will the anticipated UK/EU regulatory approval impact Orthocell’s revenue trajectory in 2027?
- What clinical outcomes from nerve-sparing prostate surgery will influence surgeon adoption in the US?
- Can Orthocell sustain its US commercial momentum amid increasing competition in regenerative nerve repair?